Cognitive-behavioral therapy for panic disorder: current status.

D H Barlow

Home/Archive/PubMed

PubMed · 9078992

Cognitive-behavioral therapy for panic disorder: current status.

D H Barlow

View original source ↗Export metadata ↓

Abstract

Controlled clinical trials evaluating cognitive-behavioral approaches for panic disorder are rapidly accumulating. In the aggregate, these studies suggest substantial efficacy for cognitive-behavioral approaches in both the short and long term. Summaries and meta-analyses of these results are briefly described, but new evidence is also presented indicating that, in this chronic condition, patients continue to experience some exacerbations and remissions over the long term. Current attempts to evaluate combination psychosocial and pharmacologic approaches are described as well as the beginnings of efforts to develop more powerful treatments for panic disorder with or without agoraphobia.

Explore related subjects

Alprazolam Cognitive Behavioral Therapy Combined Modality Therapy Controlled Clinical Trials as Topic Humans Meta-Analysis as Topic Panic Disorder Treatment Outcome Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

D H Barlow. 1997. Cognitive-behavioral therapy for panic disorder: current status.. https://pubmed.ncbi.nlm.nih.gov/9078992/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers.

OBJECTIVE: The antifungal drug ketoconazole (KTZ) is known as an inhibitor of, especially, the CYP3A subfamily, which catalyzes the metabolism of a large variety of drugs. Interactions between KTZ and CYP3A substrates have been reported both in vivo and in vitro. Most of them, however, involved the KTZ racemate. KTZ racemate and the separate enantiomers, 2R,4R; 2R,4S; 2S,4S, and 2S,4R, were evaluated for their selectivity in inhibiting alprazolam and quinine metabolism. METHODS: The inhibition of alprazolam and quinine metabolism was studied in an in vitro system of human liver microsomes (HLM), recombinant of CYP3A4 and CYP3A5. The concentrations of formed 3-hydroxyquinine and 4- and alpha-hydroxyalprazolam were measured by HPLC and LC-MS, respectively. RESULTS: Quinine 3-hydroxylation was catalyzed to a similar extent by CYP3A4 and CYP3A5. The formation rate of 4-hydroxyalprazolam was higher than that of alpha-hydroxyalprazolam for each HLM, CYP3A4 and CYP3A5. KTZ racemate and enantiomers showed differential inhibitory effects of quinine and alprazolam metabolism. Quinine metabolism catalyzed by HLM, CYP3A4 and CYP3A5 was potently inhibited by the trans-enantiomer KTZ 2S,4S, with IC(50) value of 0.16 microM for HLM, 0.04 microM for CYP3A4 and 0.11 microM for CYP3A5. The same enantiomer showed the lowest IC(50) values of 0.11 microM for HLM and 0.04 microM for CYP3A5 with respect to alprazoalm 4-hydroxylation and also the same pattern for alprazolamalpha-hydroxylation, 0.13 microM for HLM and 0.05 microM for CYP3A5. Alprazolam metabolism (both alpha- and 4- hydroxylations) catalyzed by CYP3A4 was inhibited potently by the cis-enantiomer KTZ 2S,4R, with IC(50) values of 0.03 microM. CONCLUSIONS: Alprazolam and quinine metabolism is catalyzed by both CYP3A4 and CYP3A5. The present study showed that different KTZ enantiomers inhibit CYP3A4 and CYP3A5 to different degrees, indicating that structural differences among the enantiomers would be related to their inhibitory potency on these two enzymes.

Alprazolam↗

PubMed2006

Alprazolam induced conformational change in hemoglobin.

Alprazolam (ALP) is a widely prescribed sedative and antidepressant benzodiazepine group of drugs. The wide uses of this drug lead us to investigate its possible interaction with hemoglobin (Hb). Spectrophotometric and spectofluorimetric studies showed strong binding of ALP with Hb. Circular dichroic spectra showed that alpha-helical structure of Hb-subunits has been largely changed. On ALP treatment partial pressure of O(2) is increased in the blood indicating release of O(2) from erythrocytes. Further, the binding of ALP-induced conformational changes in Hb resulting in larger Hb particle size was demonstrated by dynamic light scattering experiment. Thus, the present study unambiguously raises question of danger of random usage of ALP, which binds with and changes the function of Hb.

Alprazolam↗

PubMed2006

Raman mapping of low-content API pharmaceutical formulations. I. Mapping of Alprazolam in Alprazolam/Xanax tablets.

PURPOSE: Raman chemical imaging of API was carried out to provide information on whether there is any structural difference between the commercial Xanax and Alprazolam tablets (the API content less than 1% w/w in both cases) in the batches with low and good recovery. MATERIALS AND METHODS: Raman mapping spectra were collected from the flattened surfaces of six tablets. The mapping spectra were analyzed by principal component analysis because the Raman signal of the API (Alprazolam) was not reliably detected from the raw spectra. The complexity of the obtained grey-scale score images was such that no information about the domain sizes of the API could be obtained and thus binarization was applied to simplify these images. RESULTS: It was found that reliable detection of the Raman signal of the API was only achieved after principal component analysis was employed with the mapping being facilitated by a surprising similarity between a high principal component loading and the spectrum of the API. The binarization was successful only if the outlying pixels in the score images are eliminated. SUMMARY: The final chemical images represent quantitative characterization of the domains of the API in the tablets in contrast to chemical images of tablets that have been reported so far in the literature which have usually been descriptive only. The abundance of Alprazolam in all six tablets of Xanax and Alprazolam, respectively, was very similar. The domain sizes were found to be below 75 mum in diameter for all the tablets analyzed.

Alprazolam↗